NYSE:PFE News 22 June 2025

Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Market Performance (Sept. 30 & Oct. 1) U.S. stock markets closed Sept. 30 higher, ending the month on a positive note. The S&P 500 closed at 6,688.46 (+0.41%), the Dow at 46,397.89 (+0.18%), and the Nasdaq at 22,660.01 (+0.31%) reuters.com.

1 October 2025

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow

30 September 2025

Healthcare · NYSE:PFE · Pharmaceuticals · Policy · Politics · US News

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 reuters.com). Its trailing P/E is 12.64× reuters.com (ex. special items) and forward P/E ~7.7×

30 September 2025

Business News · NYSE:PFE · Pharmaceuticals · Stock Market · Stocks · Trump Administration · Weight Loss

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com

21 August 2025

Biotech · Healthcare · Industry News · Medical Innovations · NASDAQ:CRL · NYSE:LLY · NYSE:MDT · NYSE:NVO · NYSE:PFE · NYSE:TAK · Pharmaceuticals

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology

18 August 2025

Biotech · Health · Medical News · NASDAQ:GBT · NASDAQ:MDGL · NASDAQ:TNXP · NYSE:NVO · NYSE:PFE · Pharma · Research

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing

16 August 2025

Biotechnology · Health News · Medical Innovations · Mergers & Acquisitions · NASDAQ:BNTX · NASDAQ:CVAC · NASDAQ:TNXP · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharmaceuticals

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer Inc., in collaboration with BioNTech, co-developed the first FDA-approved mRNA COVID-19 vaccine, Comirnaty. Roche Holding AG is the world’s largest biotech company and a leader in oncology treatments (Herceptin) and diagnostics. Moderna, Inc. pioneered mRNA vaccine technology and its

22 June 2025

Biotechnology · Health · Industry Leaders · Innovation · NASDAQ:BNTX · NASDAQ:CRSP · NASDAQ:ILMN · NASDAQ:LNZA · NASDAQ:MRNA · NYSE:DNA · NYSE:PFE · Science

NYSE:PFE News 22 June 2025 - 1 October 2025